Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
about
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineDifferential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelChemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionalphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialEvaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoEvaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNASignificance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group StudyAssociation of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.Dose-dense chemotherapy for breast cancer.Protein expression patterns of cell cycle regulators in operable breast cancer.Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy.TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study.Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapyPostoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
P2860
Q24240568-5B8C54CF-6681-4BEB-80ED-74797F640F57Q26853619-6FC23B27-61F7-401D-9193-666904E4CC76Q28728830-BE2270E0-652D-470B-A113-8D8570350D31Q30399577-BFF390F9-5734-4BB9-A268-3521DD1BCB79Q33830446-71F4862B-13C5-450D-9C06-09389FABD26EQ34010867-9C181660-4C22-4EFB-A811-0DD0A16B7323Q34468964-010C9689-71DE-4950-89C9-770F51ECA7CEQ34640536-711EE1F0-B57C-4122-9308-A9A91ABE58CFQ35651423-348C4D8A-0428-4FA2-9813-E485684176BDQ35801713-0D10FC28-9D8B-4004-A48A-083AED7FA480Q36151341-BECE6D05-8249-40D1-BC39-9EFF96409FB0Q37638287-DA1FBAFF-4B1B-4A21-B036-515367D31CB8Q38009885-416A65FD-0137-477B-A6E0-D8C9BE4AF45BQ38630291-8A2C1AF0-BB68-4265-91BC-3408B21C6D6CQ38699879-BD56AC4D-AA60-4960-92DC-C1ACB049F5B0Q39719978-C8E2D5F3-D41F-4041-83B5-600DC2C54133Q44294451-F5B5B38C-B426-492F-8B84-7AB984954241Q44763826-80EF6E10-FDBD-4A7F-B9D2-32C7B921C89CQ53657728-F67AD31E-9F57-47C5-8742-58B4FA72E58CQ54522260-D92C2879-0EF3-4DEB-A4F8-A4164FECF908Q57152794-C94E6913-8EF9-4A62-921A-17FED66ACF57Q57904482-90D63235-AA6B-4920-ABE1-50FB455D0AAF
P2860
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Postoperative dose-dense seque ...... ized phase III trial HE 10/00.
@ast
Postoperative dose-dense seque ...... ized phase III trial HE 10/00.
@en
type
label
Postoperative dose-dense seque ...... ized phase III trial HE 10/00.
@ast
Postoperative dose-dense seque ...... ized phase III trial HE 10/00.
@en
prefLabel
Postoperative dose-dense seque ...... ized phase III trial HE 10/00.
@ast
Postoperative dose-dense seque ...... ized phase III trial HE 10/00.
@en
P2093
P50
P356
P1433
P1476
Postoperative dose-dense seque ...... mized phase III trial HE 10/00
@en
P2093
A Polichronis
C Karanikiotis
C Papadimitriou
D Bafaloukos
D Pectasides
E Briasoulis
E Samantas
E Tzorakoeleftherakis
G Fountzilas
P304
P356
10.1093/ANNONC/MDM539
P577
2007-11-27T00:00:00Z